FDA will be key in pharma's adoption of personalized medicine

09/26/2013 | Forbes

The FDA's attitude will be crucial to the willingness of drugmakers to adopt personalized medicine and its wider application, writes Henry I. Miller, the founding director of the FDA Office of Biotechnology. Huge development costs could be imposed by the regulatory demand for extensive clinical trials to prove new drugs' safety as well as the need to develop biomarkers to go with these drugs, he writes. Furthermore, the diminished revenue potential may in the end become unsustainable for drugmakers, he writes.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA